DPP System for Type 1 Diabetes
(SMART02 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This research study is testing an investigational dual-port insulin patch pump that integrates a continuous glucose monitor (CGM) in adults with type 1 diabetes. The goal of the study is to better understand how insulin delivery near a CGM sensor affects glucose readings and to collect data to support development of a combined insulin pump and CGM system.
People with type 1 diabetes require lifelong insulin therapy. Many use insulin pumps and CGMs, but these systems usually involve wearing multiple devices at different body sites. Managing several devices can increase treatment burden and may contribute to skin irritation, device failures, and challenges with glucose control.
This study is conducted in two in-patient parts. In Part A, participants will wear three investigational devices at the same time while glucose levels are closely monitored using laboratory blood tests and a commercial CGM. This part of the study is designed to measure how basal and bolus insulin delivery near the CGM sensor affects sensor accuracy and how quickly the sensor signal recovers after insulin delivery.
In Part B, participants will wear one investigational device while trained study staff use CGM information from the integrated sensor to guide insulin delivery recommendations generated by an automated glucose control algorithm. Insulin delivery decisions will be closely supervised, and glucose levels will be frequently monitored.
Participants will stay at the clinical research center for short, controlled study visits. Safety will be monitored throughout the study, with predefined procedures for treating low or high blood sugar. The information collected will be used to support further development of an integrated insulin pump and CGM system for people with type 1 diabetes.
Are You a Good Fit for This Trial?
This trial is for adults (18+) with type 1 diabetes for at least a year, who have been using insulin therapy (pump or injections) for at least 3 months and take between 30-100 units of insulin daily. People can't join if they have serious health issues, recent severe low blood sugar or diabetic ketoacidosis, are pregnant, or can't safely wear the devices.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Part A: Sensor Characterization
Participants undergo a 1.5-day in-patient stay using the DPP System to assess sensor response to basal and bolus insulin delivery.
Part B: Automated Glycaemic Control Feasibility
Participants undergo a 2.5-day in-patient stay using the DPP System and an automated glycaemic control algorithm to evaluate glucose control.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- DPP System (Insulin Pump and Continuous Glucose Monitoring Platform)
Trial Overview
The study tests a new dual-port insulin patch pump that combines an insulin pump and continuous glucose monitor in one device. Participants will use either one or three of these investigational devices during short hospital stays to see how well the system works and affects glucose readings.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Sensor characterization, Part "A": Participants will undergo a 1.5-day in-patient stay using the DPP System. The pump and the CGM functions of the DPP System are controlled by separate smartphone applications. Blood glucose will be monitored with a Yellow Springs Instruments (YSI) glucose analyzer and a separate commercial CGM (Dexcom G7 CGM System). Participants will also undergo euglycemic glucose clamp testing to assess sensor response to basal and bolus insulin delivery. Automated glycaemic control, "Part B": Participants will undergo a 2.5-day in-patient stay using the DPP System and an automated glycaemic control (AGC) algorithm. During this period, they will consume standardized meals and engage in standardized exercise to evaluate glucose control.
Find a Clinic Near You
Who Is Running the Clinical Trial?
ClinSurge Research
Lead Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborator
PharmaSens AG, Biel/Bienne Switzerland
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.